USSTOCK.TODAY
Regular Market
Log in Sign up

Revolution Medicines Receives Pancreatic Cancer Treatment Approval and Increases Stake

The Motley Fool +1 · ·by G4L

RVMD Revolution Medicines Inc
$200.15 +4.09%
View chart & analysis →
  1. 1The US FDA approved daraxonrasib for the treatment of pancreatic cancer in August 2026.
  2. 2RBC Capital Markets projected peak annual sales for daraxonrasib at $11.5 billion.
  3. 3Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines to 26.5% in Q3 2026.

So what's the key point?

A new pancreatic cancer treatment was approved in the US. Because this drug is expected to reach $11.5 billion in annual sales, more shares of Revolution Medicines were purchased.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Revolution Medicines Receives FDA Approval for Pancreatic Cancer Treatment, Raising Royalty Pharma Revenue Expectations The Motley Fool +1 · yesterdayRevolution Medicines beats revenue estimates with RASONQUE launch Earnings Whispers +3 · 5d agoRevolution Medicines Obtains US Approval for Pancreatic Cancer Treatment Razonc The Motley Fool +2 · Oct 28
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news